Letters were sent about ibrutinib, daclizumab, aflibercept, valproate medicines, and arsenic trioxide.
In July 2017, the following letters were sent to relevant healthcare professionals to inform them of updated safety information:
- Imbruvica▼(ibrutinib) and risk of hepatitis B reactivation: hepatitis B virus status to be established before initiating treatment
- Zinbryta▼ (daclizumab): restrictions of use of in view of fatal fulminant liver failure
- Aflibercept (Zaltrap▼) concentrate for solution for infusion 200 mg/8 mL: some batches contain previous Patient Information Leaflet; inform patients of warnings for heart failure
- Valproate medicines: only for use when no other treatment is effective or tolerated in girls, women of childbearing potential, and women who are pregnant or planning pregnancy; important actions required — letter for specialists, specialist nurses/midwives, and general practitioners and letter for pharmacists
- Shortage of Trisenox (arsenic trioxide, 1 mg/ml concentrate for solution for infusion): replacement with imported arsenic trioxide injection 1 mg/ml (Phenasen) during supply shortage — prescribers should refer responsibilities for off-label or unlicensed use of medicines
Article citation: Drug Safety Update volume 11 issue 1, August 2017: 4.